Replies to post #218791 on Biotech Values

[mcbio]

GILD 1Q18 CC slides

I see only one HBV asset in the pipeline (in Phase 1). I wonder if they have any interest in what ASMB is doing in the HBV space give the recent P1 PoC data (yes, very early and I'm biased of course).